Results (4374)
European Rare Blood Disorders Platform
First published:
25/07/2025
Austria
Belgium
Cyprus
Denmark
Finland
France
Germany
Greece
Hungary
Ireland
Italy
Luxembourg
Netherlands
Poland
Portugal
Spain
Sweden
United Kingdom
Data source
Human
Disease registryEMA/2020/46/TDA, Lot 1 – ROC25 Refinement of enhanced Ames test conditions for N-nitrosamines MUTAMIND2
Germany
EU PAS number:
EUPAS1000000684
First published:
25/07/2025
StudyOngoing
Alma Mater Studiorum Università di Bologna (UNIBO)
Italy
First published:
25/07/2025
InstitutionEducational InstitutionENCePP partner
Peking University School of Public Health
China
First published:
25/07/2025
InstitutionEducational Institution
The Health Research Institute Hospital La Fe (IIS La Fe)
Spain
First published:
25/07/2025
InstitutionOther
European Interbalkan Medical Center (EIMC)
Greece
First published:
25/07/2025
InstitutionHospital/Clinic/Other health care facility
Fundación Piel Sana AEDV
Spain
First published:
25/07/2025
InstitutionLaboratory/Research/Testing facility
Vall d’Hebron University Hospital - Vall d’Hebron Research Institute (HUVH/VHIR)
Spain
First published:
24/07/2025
InstitutionHospital/Clinic/Other health care facilityLaboratory/Research/Testing facility
Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Austria
First published:
24/07/2025
InstitutionNot-for-profitOtherENCePP partner
Hospices Civils de Lyon (HCL)
France
First published:
24/07/2025
InstitutionEducational InstitutionHospital/Clinic/Other health care facility
CROSSROADS-2: Clinical Characteristics, Treatment Patterns, and Treatment Outcomes Among Users of Tezspire: An Electronic Medical Record (EMR) study (20220066)
United States
EU PAS number:
EUPAS1000000053
First published:
24/07/2025
StudyOngoing
Faculty of Pharmacy, Medical University - Sofia, Bulgaria
Bulgaria
First published:
24/07/2025
InstitutionEducational Institution
IATROS
First published:
24/07/2025
France
Data source
Human
Hospital inpatient recordsHospital outpatient visit recordsOtherProton therapy for head and neck cancer therapy: A real-world data case study from Bulgaria
Bulgaria
EU PAS number:
EUPAS1000000569
First published:
24/07/2025
StudyFinalised
Real-world effectiveness of dabrafenib and trametinib in patients with BRAF-positive melanoma treated in routine Bulgarian clinical practice
Bulgaria
EU PAS number:
EUPAS1000000567
First published:
24/07/2025
StudyFinalised
An Observational Post-authorization Long-term Follow-up Study to Characterize the Effectiveness and Safety of HEMGENIX® (Etranacogene Dezaparvovec) in Patients with Hemophilia B (CSL222_4001)
Austria
Belgium
Denmark
Finland
France
Germany
Ireland
Italy
Netherlands
Norway
Spain
Sweden
Switzerland
United Kingdom
United States
EU PAS number:
EUPAS106066
First published:
24/07/2025
StudyPlanned
Non-interventional prospective study in patients with pulmonary fibrosis treated with nintedanib participating in a patient support program in Spain, to describe patient satisfaction with the program and to monitor quality of life. BALANCE Study
Spain
EU PAS number:
EUPAS1000000550
First published:
22/07/2025
StudyOngoing
Prospective Non-interventional Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment (CABOCARE)
Austria
Germany
EU PAS number:
EUPAS108004
First published:
22/07/2025
StudyOngoing
Effectiveness and Safety of SMART BoNT-A therapy with Dysport® in patients with post-stroke chronic upper limb spasticity in real-life setting (SMART-NIS)
Germany
EU PAS number:
EUPAS107722
First published:
22/07/2025
StudyOngoing
Evaluating the Effectiveness of Eliquis® Additional Risk Minimization Measures in Kingdom of Saudi Arabia.
Saudi Arabia
EU PAS number:
EUPAS1000000270
First published:
22/07/2025
StudyOngoing
A multi-center prospective non-interventional study to understand the use of next generation sequencing (NGS) in patients with metastatic non-small cell lung cancer and metastatic colorectal cancer in Belgium.
Belgium
EU PAS number:
EUPAS107702
First published:
22/07/2025
StudyDiscontinued
Post Marketing Surveillance of Effectiveness (All-Cause Mortality) of Posaconazole Injection and Tablet Treatment of Invasive Aspergillosis in Chinese patients (MK-5592-141)
China
EU PAS number:
EUPAS108481
First published:
22/07/2025
StudyFinalised
DARWIN EU® - Association of venous thromboembolism with non-steroidal anti-inflammatory drug use in women 15-49 years using hormonal contraceptives
Denmark
Norway
Spain
United Kingdom
EU PAS number:
EUPAS1000000443
First published:
21/07/2025
StudyFinalised
Real World Outcomes of Patients Treated with Vericiguat in German Routine Care (ROVER)
Germany
EU PAS number:
EUPAS1000000221
First published:
21/07/2025
StudyOngoing
Assessing the impact of earlier access to biologics on remission and natural course of asthma (GLEAM)
Argentina
Belgium
Brazil
Bulgaria
Canada
Colombia
Denmark
Estonia
France
Greece
India
Ireland
Italy
Japan
Korea, Republic of
Kuwait
Mexico
Norway
Poland
Portugal
Saudi Arabia
Singapore
Spain
Taiwan
United Arab Emirates
United Kingdom
United States
EU PAS number:
EUPAS1000000530
First published:
21/07/2025
StudyFinalised
Long-Acting Inhalable Drugs for Chronic Obstructive Pulmonary Disease
Canada
EU PAS number:
EUPAS1000000325
First published:
21/07/2025
StudyOngoing
Ocrelizumab Pregnancy Registry
Germany
United States
EU PAS number:
EUPAS31342
First published:
21/07/2025
StudyFinalised
Additional risk minimisation measures for Ruconest - European survey of educational materials
European Union
United Kingdom
EU PAS number:
EUPAS1000000680
First published:
21/07/2025
StudyOngoing
id.DRIVE (former COVIDRIVE) study of brand-specific COVID-19 vaccine effectiveness against severe COVID-19 disease in Europe
France
Germany
Italy
Spain
United Kingdom
EU PAS number:
EUPAS42328
First published:
21/07/2025
StudyOngoing
An Active Surveillance Study to Monitor the Real-World Long-term Safety of Somatrogon Among Paediatric Patients in Europe
France
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS107217
First published:
21/07/2025
StudyPlanned
STudy of Real world vaccinE Effectiveness of maTernal RSVpreF vaccinatiON against respiratory syncytial virus (RSV) in hospitalised infants in Australia (STREETON)
Australia
EU PAS number:
EUPAS1000000598
First published:
21/07/2025
StudyPlanned
Post-Authorization Active Surveillance Safety Study Using Secondary Data to Monitor Real World Safety of mRESVIA (mRNA-1345) for Respiratory Syncytial Virus (RSV) in the United States
United States
EU PAS number:
EUPAS1000000667
First published:
21/07/2025
StudyOngoing
DARWIN EU® – Trends in utilisation of Attention-Deficit Hyperactivity Disorder (ADHD) Medications
Denmark
Germany
Spain
Sweden
EU PAS number:
EUPAS1000000678
First published:
21/07/2025
StudyOngoing
A Test-Negative Case-Control Study to Evaluate the Effectiveness of V116, CAPVAXIVE™ Against Pneumococcal Pneumonia in Older Adults
Canada
United States
EU PAS number:
EUPAS1000000640
First published:
17/07/2025
StudyPlanned
Exploring Lipid Profiles and Predicting ASCVD Risk in Greek Cardiac Patients: A Retrospective Cohort Study (The CARDIO study)
Greece
EU PAS number:
EUPAS1000000671
First published:
17/07/2025
StudyOngoing
SJD Barcelona Children's Hospital Database
First published:
16/07/2025
Spain
Data source
Human
Emergency care discharge recordsHospital discharge recordsHospital inpatient recordsHospital outpatient visit recordsPharmacy dispensing recordsUse cases for development, optimisation and implementation of artificial intelligence methods for real world data analyses in regulatory decision-making and health technology assessment along the product lifecycle (Real4Reg)
Denmark
Finland
Germany
Portugal
EU PAS number:
EUPAS105544
First published:
16/07/2025
StudyOngoing
Real-World (RW) Elranatamab Administration: Step Up Dosing (SUD), Treatment Patterns, and Healthcare Resource Utilization (HCRU) in Japan MDV Data (SUMMIT)
Japan
EU PAS number:
EUPAS1000000503
First published:
16/07/2025
StudyOngoing